Floatz logo

3-(2,2,2-TRIMETHYLDIAZANIUMYL)PROPANOATE

Myocardial Ischemia

Burnasyan Federal Medical Biophysical CenterSmall moleculePhase 4 / ApprovedDormant
BB
69/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Myocardial Ischemia cohort.

Asset / SponsorPhaseRating
Ranolazine
East Carolina University
Phase 4A
ATENOLOL
Xintong Pharmacy Company
Phase 4BBB
Aspirin
Rajaie Cardiovascular Medical and Research Center
Phase 4BBB
Nebido
Sheffield Teaching Hospitals NHS Foundation Trust
Phase 4BB
Hydrochlorothiazide
The George Institute
Phase 4BB

View all 27 →

Same molecule, other indications

3-(2,2,2-TRIMETHYLDIAZANIUMYL)PROPANOATE is also rated in:

stroke disorderDormant
BB
Indicative · Phase 4
69 / 100
View asset →
renal cell carcinomaActive
CCC
Indicative · Phase 1/2
52 / 100
View asset →
kidney cancerActive
CC
Indicative · Phase 1/2
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →